Targeting the Microbiome to Overcome Resistance

Rebecca C Simpson; Erin Shanahan; Richard A Scolyer; Georgina V Long

doi:10.1016/j.ccell.2021.01.016

Targeting the Microbiome to Overcome Resistance

Cancer Cell. 2021 Feb 8;39(2):151-153. doi: 10.1016/j.ccell.2021.01.016.

Authors

Rebecca C Simpson¹, Erin Shanahan², Richard A Scolyer³, Georgina V Long⁴

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia.
² Charles Perkins Centre, The University of Sydney, Sydney, Australia; School of Life and Environmental Science, Faculty of Science, The University of Sydney, Australia.
³ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.
⁴ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: georgina.long@sydney.edu.au.

PMID: 33561397
DOI: 10.1016/j.ccell.2021.01.016

Abstract

Immune checkpoint inhibition has revolutionized the treatment of many cancers, including melanoma. However, primary and acquired resistance remain key challenges for the field. Promising results from a phase I clinical trial recently published in Science highlight the potential of modulating the microbiome via fecal transplant to overcome resistance to immunotherapy.

Publication types

Comment

MeSH terms

Humans
Immune Checkpoint Inhibitors
Immunotherapy
Melanoma* / drug therapy
Melanoma* / genetics
Microbiota*

Substances

Immune Checkpoint Inhibitors